Promoter methylation of GATA4, WIF1, NTRK1 and other selected tumour suppressor genes in ovarian cancer
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23746174
PII: file/5683/FB2013A0010.pdf
Knihovny.cz E-resources
- MeSH
- Adaptor Proteins, Signal Transducing genetics metabolism MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- DNA Methylation genetics MeSH
- Young Adult MeSH
- Tumor Suppressor Proteins genetics metabolism MeSH
- Ovarian Neoplasms genetics pathology MeSH
- Promoter Regions, Genetic * MeSH
- Receptor, trkA genetics metabolism MeSH
- Repressor Proteins genetics metabolism MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Case-Control Studies MeSH
- GATA4 Transcription Factor genetics metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adaptor Proteins, Signal Transducing MeSH
- GATA4 protein, human MeSH Browser
- Tumor Suppressor Proteins MeSH
- Receptor, trkA MeSH
- Repressor Proteins MeSH
- GATA4 Transcription Factor MeSH
- WIF1 protein, human MeSH Browser
Ovarian cancer is the leading cause of death from gynaecologic tumours, but the molecular and especially epigenetic events underlying the transformation are poorly understood. Various methylation changes have been identified and show promise as potential cancer biomarkers. The aim of this study was to investigate promoter methylation of selected tumour suppressor genes in ovarian cancer by comparison with normal ovarian tissue. To search for epigenetic events we used methylation-specific multiplex ligation-dependent probe amplification to compare the methylation status of 44 tissue samples of ovarian cancer with 30 control samples. Using a 20% cut-off for methylation, we observed significantly higher methylation in genes NTKR1, GATA4 and WIF1 in the ovarian cancer group compared with the control group. These findings could potentially be used in screening of ovarian cancer, and may have implications for future chemotherapy based on epigenetic changes.
